The EU AI Act is the world's first comprehensive law governing artificial intelligence, and healthcare sits squarely in its highest-scrutiny tier. If you are building AI that touches patient care, clinical decisions, or health data for the European market, most of what you build will be classified as high-risk. That classification carries real obligations: risk management, data governance, human oversight, transparency, and record-keeping that you must be able to demonstrate, not just describe. The obligations phase in over time, but the architecture decisions that determine whether you can meet them are being made right now.
The EU AI Act sorts AI systems into tiers by risk. A spam filter is minimal risk. A chatbot that recommends a restaurant is limited risk. But AI used in medical contexts, anything that informs diagnosis, triage, treatment, or the management of a health condition, generally falls into the high-risk category, especially where it overlaps with the EU medical device framework. High-risk does not mean prohibited. It means regulated. You can build and deploy it, but you have to prove it meets a defined set of obligations.
This matters for any company building AI companions, clinical decision support, patient communication tools, or health-data interpretation. If your product reaches European users and touches health, you should assume high-risk classification and design for it from the start. Retrofitting compliance into a system that was never built for it is far more expensive than building it in.
The high-risk requirements are not abstract principles. They are concrete, demonstrable controls. The recurring theme across all of them is the same: you must be able to show, with evidence, that the system did what it was supposed to do and did not do what it was not allowed to do.
The EU AI Act does not switch on all at once. Its obligations arrive in stages. Some prohibitions and foundational duties applied first, and the substantial high-risk obligations relevant to healthcare AI phase in on deadlines in December 2027 and August 2028. That staged timeline is not a reason to wait. The systems being designed and funded today are the ones that will need to demonstrate compliance when those deadlines arrive, and the architectural choices that make compliance possible cannot be added at the last minute.
A high-risk healthcare AI system has to demonstrate identity controls, consent handling, human oversight, and an auditable record of its decisions. None of those can be convincingly retrofitted onto a system that logged nothing and enforced nothing. The time to build the evidence trail is before you need it.
Many AI governance tools work by watching the model's output after it responds: scoring it for toxicity, flagging bias, reviewing logs after the fact. That is useful, but it cannot satisfy obligations that are fundamentally about control before the system acts. You cannot prove who was authorized to make a request, what data the model was permitted to use, or that consent was verified, by looking only at the output. The proof has to come from the layer that enforces those rules before the model ever sees the prompt.
This is the architectural distinction that separates systems that can demonstrate compliance from systems that can only hope to. Governance that runs before the model, binding identity, consent, and policy to every interaction and recording each decision in a tamper-evident log, produces exactly the evidence the high-risk obligations call for.
MiAngel built its trust layer, MiAngel Middleware AI (GMAI), to enforce governance before the AI model acts, not after. Every interaction is identity-bound, consent-verified, policy-constrained, and recorded in a tamper-evident, hash-linked audit trail. That design maps directly onto the kinds of controls high-risk obligations describe: traceable record-keeping, human oversight, data governance, and transparency. DeBrah, the AI companion built on GMAI, is the working proof that the infrastructure functions in production.
To be precise about status: meeting the EU AI Act is a structured conformity process, and formal attestations and certifications are milestones a company works toward, not switches that flip on day one. What you can do today is build on an architecture designed to produce the required evidence, so that when the obligations apply, the foundation is already in place rather than scrambled together.
When governance is enforced before the model acts and every decision is logged in a tamper-evident trail, the evidence the EU AI Act asks for is a byproduct of how the system runs, not a separate compliance project bolted on later.
It can. Like other EU digital regulations, its reach extends to systems whose output is used in the EU, so a non-EU company serving European users should plan for it.
No. High-risk systems are permitted but regulated. They must meet defined obligations around risk management, data governance, human oversight, transparency, and record-keeping.
They phase in over time, with the substantial high-risk obligations relevant to healthcare AI arriving on deadlines in December 2027 and August 2028.
Some controls can be added, but the ones that matter most, identity binding, consent enforcement, and an auditable decision trail, depend on architecture that is very hard to retrofit. Building for them now is far cheaper than retrofitting later.
See what governed AI looks like in production.
Meet DeBrah